Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK

Abstract

Revascularisation and myocardial infarction were associated with the highest incremental costs following a CV event. On the basis of real-world data, the economic burden of CV events in the UK is substantial, particularly among those with greater comorbidity burden.